Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.60 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.46 |
| ▸ | TLR4 | O00206 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28215651 | 0.99 | TLR8 (0.59) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL20135691 | 0.82 | TLR8 (0.57) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL27004828 | 0.82 | IRAK4 (0.44) | TLR8IRAK4 | |
| SCHEMBL20135108 | 0.82 | TLR8 (0.57) | TLR8TLR7TLR9TLR4IRAK4 | |
| Hydrochloric Acid SCHEMBL30508248 | 0.81 | TLR8 (0.56) | TLR8TLR7TLR9TLR4IRAK4 | |
| Hydrochloric Acid SCHEMBL28215589 | 0.81 | TLR8 (0.56) | TLR8TLR7TLR9TLR4IRAK4 | |
| Hydrochloric Acid SCHEMBL28215605 | 0.81 | TLR8 (0.56) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL15345154 | 0.79 | TLR8 (0.39) | TLR8IRAK4 | |
| SCHEMBL20809468 | 0.78 | TLR8 (0.52) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL27004838 | 0.78 | TLR8 (0.38) | TLR8IRAK4JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | TLR8 1204/4885TLR7 843/4885TLR9 113/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | TLR8 1209/4885TLR7 795/4885TLR9 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.